PB 49 of 2021
National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2021 (No. 5)
I, NIKOLAI TSYGANOV, Assistant Secretary (Acting), Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, and delegate of the Minister for Health and Aged Care, make the following determination.
Dated 27 May 2021
NIKOLAI TSYGANOV
Assistant Secretary (Acting)
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health
1 Name
(1) This instrument is the National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2021 (No. 5).
(2) This instrument may also be cited as PB 49 of 2021.
2 Commencement
(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.
Commencement information |
Column 1 | Column 2 | Column 3 |
Provisions | Commencement | Date/Details |
1. The whole of this instrument | 1 June 2021. | |
Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.
(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
3 Authority
This instrument is made under subsection 89A(3) of the National Health Act 1953.
4 Schedules
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
Schedule 1—Amendments
National Health (Continued Dispensing – Emergency Measures) Determination 2020
[1] Schedule 1, entry for Adalimumab
substitute:
Adalimumab | Injection 20 mg in 0.2 mL pre-filled syringe | Injection |
| Injection 20 mg in 0.4 mL pre‑filled syringe | Injection |
| Injection 40 mg in 0.4 mL pre-filled pen | Injection |
| Injection 40 mg in 0.4 mL pre-filled syringe | Injection |
| Injection 40 mg in 0.8 mL pre‑filled pen | Injection |
| Injection 40 mg in 0.8 mL pre‑filled syringe | Injection |
| Injection 80 mg in 0.8 mL pre-filled pen | Injection |
| Injection 80 mg in 0.8 mL pre-filled syringe | Injection |
[2] Schedule 1, after entry for Beclometasone with formoterol
insert:
Beclometasone with formoterol and glycopyrronium | Pressurised inhalation containing beclometasone dipropionate 100 micrograms with formoterol fumarate dihydrate 6 micrograms and glycopyrronium 10 micrograms (as bromide) per dose, 120 doses | Inhalation by mouth |
[3] Schedule 1, omit entry for Dalteparin
[4] Schedule 1, after entry for Desmopressin in the form Nasal spray (pump pack) containing desmopressin acetate 10 micrograms per actuation, 50 actuations, 5 mL
insert:
| Nasal spray (pump pack) containing desmopressin acetate 10 micrograms per actuation, 50 actuations,
5 mL, USP (Apotex) | Nasal |
[5] Schedule 1, entry for Folinic acid
omit:
| Injection containing calcium folinate equivalent to 300 mg folinic acid in 30 mL | Injection |
[6] Schedule 1, after entry for Galantamine in the form Capsule (prolonged release) 8 mg (as hydrobromide)
insert:
Galcanezumab | Injection 120 mg in 1 mL pre-filled pen | Injection |
[7] Schedule 1, after entry for High fat formula with vitamins, minerals and trace elements and low in protein and carbohydrate in the form Oral liquid 200 mL, 32 (KetoCal 4:1 LQ)
insert:
| Oral liquid 250 mL, 30 (KetoVie 3:1) | Oral |
| Oral liquid 250 mL, 30 (KetoVie 4:1) | Oral |
[8] Schedule 1, entry for Naproxen
omit:
[9] Schedule 1, after entry for Prochlorperazine in the form Tablet containing prochlorperazine maleate 5 mg
insert:
Progesterone | Pessary 200 mg | Vaginal |
[10] Schedule 1, after entry for Tenofovir with emtricitabine in the form Tablet containing tenofovir disoproxil phosphate 291 mg with emtricitabine 200 mg
insert:
| Tablet containing tenofovir disoproxil succinate 301 mg with emtricitabine 200 mg | Oral |
[11] Schedule 1, entry for Testosterone
omit:
| Transdermal patches 12.2 mg, 60 | Transdermal |
[12] Schedule 1, after entry for Tolvaptan in the form Pack containing 28 tablets 30 mg and 28 tablets 90 mg
insert:
| Tablet 15 mg | Oral |
| Tablet 30 mg | Oral |